QQQ   432.13 (+0.25%)
AAPL   169.12 (-2.07%)
MSFT   415.95 (+0.56%)
META   501.82 (+0.32%)
GOOGL   154.52 (-0.22%)
AMZN   183.55 (-0.04%)
TSLA   157.43 (-2.51%)
NVDA   873.80 (+1.60%)
AMD   163.55 (+2.01%)
NIO   3.84 (-1.29%)
BABA   70.09 (-0.75%)
T   16.05 (-1.17%)
F   12.18 (-0.41%)
MU   121.26 (-0.09%)
GE   155.55 (+1.20%)
CGC   6.86 (-1.72%)
DIS   114.13 (+1.04%)
AMC   2.75 (+11.34%)
PFE   25.83 (-0.31%)
PYPL   63.85 (+0.54%)
XOM   118.60 (-0.90%)
QQQ   432.13 (+0.25%)
AAPL   169.12 (-2.07%)
MSFT   415.95 (+0.56%)
META   501.82 (+0.32%)
GOOGL   154.52 (-0.22%)
AMZN   183.55 (-0.04%)
TSLA   157.43 (-2.51%)
NVDA   873.80 (+1.60%)
AMD   163.55 (+2.01%)
NIO   3.84 (-1.29%)
BABA   70.09 (-0.75%)
T   16.05 (-1.17%)
F   12.18 (-0.41%)
MU   121.26 (-0.09%)
GE   155.55 (+1.20%)
CGC   6.86 (-1.72%)
DIS   114.13 (+1.04%)
AMC   2.75 (+11.34%)
PFE   25.83 (-0.31%)
PYPL   63.85 (+0.54%)
XOM   118.60 (-0.90%)
QQQ   432.13 (+0.25%)
AAPL   169.12 (-2.07%)
MSFT   415.95 (+0.56%)
META   501.82 (+0.32%)
GOOGL   154.52 (-0.22%)
AMZN   183.55 (-0.04%)
TSLA   157.43 (-2.51%)
NVDA   873.80 (+1.60%)
AMD   163.55 (+2.01%)
NIO   3.84 (-1.29%)
BABA   70.09 (-0.75%)
T   16.05 (-1.17%)
F   12.18 (-0.41%)
MU   121.26 (-0.09%)
GE   155.55 (+1.20%)
CGC   6.86 (-1.72%)
DIS   114.13 (+1.04%)
AMC   2.75 (+11.34%)
PFE   25.83 (-0.31%)
PYPL   63.85 (+0.54%)
XOM   118.60 (-0.90%)
QQQ   432.13 (+0.25%)
AAPL   169.12 (-2.07%)
MSFT   415.95 (+0.56%)
META   501.82 (+0.32%)
GOOGL   154.52 (-0.22%)
AMZN   183.55 (-0.04%)
TSLA   157.43 (-2.51%)
NVDA   873.80 (+1.60%)
AMD   163.55 (+2.01%)
NIO   3.84 (-1.29%)
BABA   70.09 (-0.75%)
T   16.05 (-1.17%)
F   12.18 (-0.41%)
MU   121.26 (-0.09%)
GE   155.55 (+1.20%)
CGC   6.86 (-1.72%)
DIS   114.13 (+1.04%)
AMC   2.75 (+11.34%)
PFE   25.83 (-0.31%)
PYPL   63.85 (+0.54%)
XOM   118.60 (-0.90%)
Free Trial
NASDAQ:PTIX

Protagenic Therapeutics (PTIX) Stock Price, News & Analysis

→ Trump’s “Tax Free” Retirement Strategy (From Gold Safe Exchange) (Ad)
Free PTIX Stock Alerts
$1.34
-0.06 (-4.10%)
(As of 09:35 AM ET)
Compare
Today's Range
$1.34
▼
$1.35
50-Day Range
$0.88
▼
$1.82
52-Week Range
$0.68
▼
$2.32
Volume
724 shs
Average Volume
9,460 shs
Market Capitalization
$5.94 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media
PTIX stock logo

About Protagenic Therapeutics Stock (NASDAQ:PTIX)

Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. The company's lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. Protagenic Therapeutics, Inc. is headquartered in New York, New York.

PTIX Stock Price History

PTIX Stock News Headlines

April 2, 2024 | msn.com
Protagenic Therapeutics, Inc. (NASDAQ:PTIX) Q4 2023 Earnings Call Transcript
March 27, 2024 | finance.yahoo.com
Protagenic Therapeutics Successfully Concludes Third Cohort in Single Dose Portion of Phase 1 Trial for Stress-Related Neuropsychiatric Disorders
April 16, 2024 | Darwin (Ad)
Your Next Portfolio Star: Revealing 2024's Top Stock Pick
We're thrilled to offer you an exclusive look at the #1 Buy & Hold Stock of 2024. This isn't just any report. It's the culmination of rigorous analysis, expert insights, and cutting-edge financial strategies, distilled into a compelling narrative that charts the course of what we believe to be the year's most promising investment. (**By clicking the link you are subscribing to The Wealth Creation Investing Newsletter and may receive up to 2 additional free bonus subscriptions. Unsubscribing is easy.)
March 25, 2024 | finanznachrichten.de
Protagenic Therapeutics, Inc.: Protagenic Therapeutics Schedules First Q4 and FY 2023 Earnings Call
February 13, 2024 | finance.yahoo.com
Protagenic Therapeutics Achieves First Clinical Safety Milestone with its Novel Neuropeptide for the Potential Treatment of Stress-Related Disorders
December 17, 2023 | morningstar.com
Protagenic Therapeutics Inc PTIX
November 14, 2023 | seekingalpha.com
PTIX Protagenic Therapeutics, Inc.
October 13, 2023 | finanznachrichten.de
Protagenic Therapeutics, Inc.: Protagenic Therapeutics Announces Date of Annual Shareholder Meeting
April 16, 2024 | Darwin (Ad)
Your Next Portfolio Star: Revealing 2024's Top Stock Pick
We're thrilled to offer you an exclusive look at the #1 Buy & Hold Stock of 2024. This isn't just any report. It's the culmination of rigorous analysis, expert insights, and cutting-edge financial strategies, distilled into a compelling narrative that charts the course of what we believe to be the year's most promising investment. (**By clicking the link you are subscribing to The Wealth Creation Investing Newsletter and may receive up to 2 additional free bonus subscriptions. Unsubscribing is easy.)
October 13, 2023 | finance.yahoo.com
Protagenic Therapeutics Announces Date of Annual Shareholder Meeting
September 26, 2023 | finanznachrichten.de
Protagenic Therapeutics, Inc.: Protagenic Therapeutics Initiates Phase I/IIa Clinical Trial for Groundbreaking Brain Peptide PT00114
September 26, 2023 | finance.yahoo.com
Protagenic Therapeutics Initiates Phase I/IIa Clinical Trial for Groundbreaking Brain Peptide PT00114
June 17, 2023 | uk.finance.yahoo.com
PTIX - Protagenic Therapeutics, Inc.
March 24, 2023 | benzinga.com
Protagenic Therapeutics Stock (NASDAQ:PTIX), Dividends
March 22, 2023 | finanznachrichten.de
Protagenic Therapeutics, Inc.: Protagenic Therapeutics to Effect 1-for-4 Reverse Stock Split
March 22, 2023 | finance.yahoo.com
Protagenic Therapeutics to Effect 1-for-4 Reverse Stock Split
September 7, 2022 | investing.com
PTIX_old Historical Data
August 12, 2022 | finance.yahoo.com
Protagenic Therapeutics, Inc. (PTIX)
April 26, 2022 | finance.yahoo.com
Protagenic Therapeutics to Present at the B. Riley Securities Neuro and Ophthalmology Virtual Investor Conference on April 27th
January 20, 2022 | nasdaq.com
Protagenic Therapeutics, Inc. Common Stock (PTIX)
November 16, 2021 | finance.yahoo.com
Protagenic Therapeutics Announces Third Quarter 2021 Results and Business Update
August 30, 2021 | finance.yahoo.com
Protagenic Therapeutics to Host Virtual Science Review Wednesday, September 8th at 10 AM ET
August 17, 2021 | finance.yahoo.com
Protagenic Therapeutics Announces Second Quarter 2021 Results and Provides Business Update
July 23, 2021 | marketwatch.com
Protagenic Therapeutics Updates on Patient Enrollment for PT00114 Trial, Shares Lower
July 23, 2021 | apnews.com
Protagenic Therapeutics Updates Timeline for Commencement of Patient Enrollment for PT00114 ...
July 23, 2021 | finance.yahoo.com
Protagenic Therapeutics Updates Timeline for Commencement of Patient Enrollment for PT00114 Clinical Trial
See More Headlines
Receive PTIX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Protagenic Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/16/2021
Today
4/16/2024
Next Earnings (Estimated)
5/20/2024
Fiscal Year End
12/31/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:PTIX
CUSIP
N/A
CIK
1022899
Web
www.protagenic.com
Phone
212-994-8200
Fax
603-761-6223
Employees
N/A
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($1.15)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-5,000,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-101.81%
Return on Assets
-82.18%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
6.41
Quick Ratio
6.41

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.83 per share
Price / Book
1.61

Miscellaneous

Outstanding Shares
4,440,000
Free Float
2,794,000
Market Cap
$5.95 million
Optionable
Not Optionable
Beta
0.36
10 Best Cheap Stocks to Buy Now Cover
10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Dr. Garo H. Armen Ph.D. (Age 71)
    Co-Founder & Executive Chairman of the Board
  • Dr. Alexander Kenneth Arrow C.F.A. (Age 53)
    M.D., CFO & Secretary
    Comp: $150k
  • Dr. Andrew Slee (Age 74)
    Chief Operating Officer
  • Dr. Robert Benjamin Stein M.D. (Age 73)
    Ph.D., Chief Medical Officer & Director

Key Competitors

View All Competitors

Insiders

View All Insider Transactions

PTIX Stock Analysis - Frequently Asked Questions

How have PTIX shares performed in 2024?

Protagenic Therapeutics' stock was trading at $0.99 at the start of the year. Since then, PTIX shares have increased by 35.4% and is now trading at $1.34.
View the best growth stocks for 2024 here.

When is Protagenic Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our PTIX earnings forecast.

How were Protagenic Therapeutics' earnings last quarter?

Protagenic Therapeutics, Inc. (NASDAQ:PTIX) posted its quarterly earnings results on Tuesday, November, 16th. The company reported ($0.05) earnings per share for the quarter, topping analysts' consensus estimates of ($0.08) by $0.03.

How do I buy shares of Protagenic Therapeutics?

Shares of PTIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PTIX) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners
Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!
Priority Gold
He Is Giving Away Bitcoin
Crypto Swap Profits
This Apple-like Innovator is Revolutionizing Healthcare
Wall Street Star
Healthcare Takes A Big Step Forward With The Help Of AI
The Bull Report
The "Smart Money" Is Ready for May 1st Are You?
Stansberry Research
Options trading has suddenly become more reliable.
Eagle Publishing
The “Perfect Storm” for Gold
Gold Safe Exchange
top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)
Traders Agency